Tenon Medical (NASDAQ:TNON) Posts Earnings Results, Misses Estimates By $3.95 EPS

Tenon Medical (NASDAQ:TNON) issued its quarterly earnings data on Thursday. The company reported ($12.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.40) by ($3.95), FiscalAI reports. Tenon Medical had a negative return on equity of 907.60% and a negative net margin of 270.09%.The company had revenue of $1.28 million for the quarter, compared to the consensus estimate of $1.54 million.

Here are the key takeaways from Tenon Medical’s conference call:

• Revenue and gross profit surged: Second-quarter revenue rose 127% year over year to $1.3 million, while gross profit increased 232% to $0.8 million. Gross margin expanded to 64% from 43%, aided by higher procedure volumes and improved fixed-cost absorption.
• Physician and distributor training events increased 98% in the first half versus the second half of 2025, supported by the new Tampa training center. Management said the facility contributed to a record monthly case volume in July and a strong start to the third quarter.
• FDA 510(k) clearance for the updated Catamaran system is expected to reduce per-procedure costs through reusable instruments and improve margins beginning in the third quarter. The company is also preparing enhancements to Symmetry Plus and additional products for potential regulatory filing and launch.
• Tenon raised $4.2 million in gross proceeds through a July 1 public offering, providing additional funding for commercial expansion, clinical research, product development, and partial repayment of convertible notes.
• The company remains loss-making, with a second-quarter net loss of $4.1 million and $1.7 million in cash at quarter-end. Operating expenses increased, and the six-month operating loss was essentially unchanged year over year despite revenue more than doubling; additional non-cash interest expense also increased the net loss.

Tenon Medical Price Performance

Shares of NASDAQ TNON traded up $0.32 during mid-day trading on Thursday, reaching $5.96. 73,962 shares of the company’s stock traded hands, compared to its average volume of 101,824. The business has a 50-day simple moving average of $11.59 and a 200 day simple moving average of $21.62. The stock has a market cap of $2.02 million, a P/E ratio of -0.13 and a beta of 1.39. Tenon Medical has a 1-year low of $4.38 and a 1-year high of $54.95.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on TNON shares. Alliance Global Partners reissued a “buy” rating on shares of Tenon Medical in a research report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tenon Medical in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

Hedge Funds Weigh In On Tenon Medical

A number of hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in shares of Tenon Medical during the first quarter valued at approximately $29,000. Geode Capital Management LLC boosted its holdings in Tenon Medical by 34.6% during the 4th quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock worth $63,000 after acquiring an additional 17,137 shares during the last quarter. Finally, DRW Securities LLC bought a new stake in shares of Tenon Medical in the 4th quarter worth $98,000. Institutional investors and hedge funds own 22.74% of the company’s stock.

Tenon Medical Company Profile

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.